Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VECTORS: Treating to a Target of Transmural Healing in Crohn's Disease
NCT06257706Phase 4Recruiting
- Sponsor
- Alimentiv Inc.
- Start
- Aug 2024
- Primary completion
- Jan 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 4 trial of vedolizumab in Crohn's disease, sponsored by Alimentiv Inc.. Started Aug 2024; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06257706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06257706.